Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Cash from Financing Activities (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Cash from Financing Activities for 4 consecutive years, with $20.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 109.95% to $20.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.4 million through Dec 2025, up 27.21% year-over-year, with the annual reading at $20.4 million for FY2025, 27.21% up from the prior year.
  • Cash from Financing Activities hit $20.3 million in Q4 2025 for Coya Therapeutics, up from $19137.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $24.2 million in Q4 2023 to a low of -$104071.0 in Q4 2022.
  • Historically, Cash from Financing Activities has averaged $6.5 million across 4 years, with a median of $1.2 million in 2024.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 23329.1% in 2023 and later tumbled 98.46% in 2025.
  • Year by year, Cash from Financing Activities stood at -$104071.0 in 2022, then surged by 23329.1% to $24.2 million in 2023, then crashed by 59.91% to $9.7 million in 2024, then soared by 109.95% to $20.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for COYA at $20.3 million in Q4 2025, $19137.0 in Q3 2025, and $19137.0 in Q1 2025.